WINDLAS BIOTECH
|
The Current P/E Ratio of WINDLAS BIOTECH is 24.37.
| Share Price | ₹771.1 | Feb 23,2026 |
| Market Cap | ₹1,626.9 Cr | |
| Earnings-TTM | ₹66.7 Cr | TTM-Consolidated Results |
| Price/Earnings | 24.37x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of WINDLAS BIOTECH
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,626.9 Cr] as on Feb 23,2026
(/) Earnings [ ₹66.7 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 24.37x ]
Thus, for WINDLAS BIOTECH , the investors are currently willing to pay 24.37 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of WINDLAS BIOTECH !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of WINDLAS BIOTECH over the last five years.
Historical PE (Price/Earnings) ratio chart of WINDLAS BIOTECH
PE Ratio Performance Analysis for WINDLAS BIOTECH
- WINDLAS BIOTECH 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 15.43x.
- WINDLAS BIOTECH 's operated at median p/e ratio of 12.02x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, WINDLAS BIOTECH 's p/e ratio peaked in Mar2025 at 35.78x.
- WINDLAS BIOTECH 's p/e ratio hit its five-year low in Mar2021 of 0x.
How does WINDLAS BIOTECH 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| WINDLAS BIOTECH | 66.75 | 24.37 | 1,626.9 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 37.78 | 415,613.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 67.41 | 167,105.0 |
| CIPLA LTD | 4,544.70 | 23.57 | 107,120.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 64.23 | 145,926.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 19.80 | 109,088.0 |
| MANKIND PHARMA LTD | 1,796.65 | 47.01 | 84,468.2 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 18.52 | 91,356.0 |
| LUPIN LTD | 4,669.18 | 21.98 | 102,611.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 19.01 | 66,792.2 |
| ABBOTT INDIA LTD | 1,524.13 | 36.92 | 56,264.2 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs WINDLAS BIOTECH 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.52x |
| Max industry PE | 67.41x |
| Median industry PE | 24.37x |
| Average industry PE | 34.60x |
You may also like the below Video Courses